Head-to-head · free
iRhythm Technologies, Inc. vs Kyntra Bio, Inc.
IRTC vs KYNB — return on capital, cash generation, margins and balance sheet side by side.
IRTC
6 / 8
measures where IRTC leads
KYNB
2 / 8
measures where KYNB leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | IRTC · FY2025 | KYNB · FY2025 |
|---|---|---|
| Revenue | $747.1M | $6.4M |
| Net income | (44.6M) | $183.5M |
| Revenue growth (yearly, multi-year) | 23.3% | -59.3% |
| Free cash flow | $34.5M | (4.8M) |
| Free cash flow margin | 4.6% | -74.7% |
| Net cash / (debt) | — | — |
| ROIC | — | — |
| Return on equity | -36.6% | — |
| Gross margin | 70.6% | 91.4% |
| Operating margin | -6.7% | -704.1% |
| Net debt / EBITDA | -13.37x | 1.06x |
Figures are as reported by each company; latest fiscal year shown.
Where iRhythm Technologies, Inc.'s cash went (FY2025)
- Capital spending
- $46.3M
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Where Kyntra Bio, Inc.'s cash went (FY2025)
- Capital spending
- $38000
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free